Blockade of stress-induced increase of glutamate release in the rat prefrontal/frontal cortex by agomelatine involves synergy between melatonergic and 5-HT2C receptor-dependent pathways

[1]  E. van Cauter,et al.  Depression: A Disorder of Timekeeping? , 2015, Perspectives in biology and medicine.

[2]  Fabio Benfenati,et al.  Acute Stress Increases Depolarization-Evoked Glutamate Release in the Rat Prefrontal/Frontal Cortex: The Dampening Action of Antidepressants , 2010, PloS one.

[3]  M. Riva,et al.  Synergistic mechanisms in the modulation of the neurotrophin BDNF in the rat prefrontal cortex following acute agomelatine administration , 2010, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[4]  R. Emsley,et al.  Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. , 2009, The Journal of clinical psychiatry.

[5]  M. Millan,et al.  Mechanisms Contributing to the Phase-Dependent Regulation of Neurogenesis by the Novel Antidepressant, Agomelatine, in the Adult Rat Hippocampus , 2009, Neuropsychopharmacology.

[6]  C. Gabriel,et al.  The novel antidepressant agomelatine reduces the release of glutamate induced by acute footshock stress in synaptosomes of prefrontal/frontal cortex , 2008 .

[7]  M. Papp,et al.  S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models , 2008, Psychopharmacology.

[8]  Grzegorz Hess,et al.  Repeated administration of imipramine attenuates glutamatergic transmission in rat frontal cortex , 2008, Neuroscience.

[9]  C. Guilleminault,et al.  Non-REM sleep instability in patients with major depressive disorder: subjective improvement and improvement of non-REM sleep instability with treatment (Agomelatine). , 2007, Sleep medicine.

[10]  F. Drago,et al.  Chronic Antidepressants Induce Redistribution and Differential Activation of αCaM Kinase II between Presynaptic Compartments , 2007, Neuropsychopharmacology.

[11]  S. Kasper,et al.  Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. , 2007, The international journal of neuropsychopharmacology.

[12]  M. Raiteri,et al.  Antidepressant treatments and function of glutamate ionotropic receptors mediating amine release in hippocampus , 2007, Neuropharmacology.

[13]  V. Bertaina-Anglade,et al.  Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model , 2006, Behavioural pharmacology.

[14]  R. Emsley,et al.  Placebo-controlled trial of agomelatine in the treatment of major depressive disorder , 2006, European Neuropsychopharmacology.

[15]  Anna Wirz-Justice,et al.  Biological rhythm disturbances in mood disorders , 2006, International clinical psychopharmacology.

[16]  E. Shink,et al.  Antidepressant action of agomelatine (S 20098) in a transgenic mouse model , 2005, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[17]  M. Raiteri,et al.  Chronic Antidepressants Reduce Depolarization-Evoked Glutamate Release and Protein Interactions Favoring Formation of SNARE Complex in Hippocampus , 2005, The Journal of Neuroscience.

[18]  M. Bourin,et al.  Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors. , 2004, Journal of psychiatry & neuroscience : JPN.

[19]  M. Millan,et al.  The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways , 2003, Journal of Pharmacology and Experimental Therapeutics.

[20]  J. Boutin,et al.  New selective ligands of human cloned melatonin MT1 and MT2 receptors , 2003, Naunyn-Schmiedeberg's Archives of Pharmacology.

[21]  M. Papp,et al.  Effect of Agomelatine in the Chronic Mild Stress Model of Depression in the Rat , 2003, Neuropsychopharmacology.

[22]  H. Lôo,et al.  Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT2C antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study , 2002, International clinical psychopharmacology.

[23]  B. Vollmayr,et al.  Learned helplessness in the rat: improvements in validity and reliability. , 2001, Brain research. Brain research protocols.

[24]  R. Whelpton,et al.  Imipramine and phenelzine decrease glutamate overflow in the prefrontal cortex—a possible mechanism of neuroprotection in major depression? , 2000, Neuroscience.

[25]  I. Anderson,et al.  Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. , 2000, Journal of affective disorders.

[26]  M. Raiteri,et al.  Entrapping of Impermeant Probes of Different Size into Nonpermeabilized Synaptosomes as a Method to Study Presynaptic Mechanisms , 2000, Journal of neurochemistry.

[27]  D. Kupfer.  Sleep research in depressive illness: Clinical implications —a tasting menu , 1995, Biological Psychiatry.

[28]  T. Wehr,et al.  Twenty-four-hour profiles of body temperature and plasma TSH in bipolar patients during depression and during remission and in normal control subjects. , 1988, The American journal of psychiatry.

[29]  J. Rostas,et al.  A rapid method for isolation of synaptosomes on Percoll gradients , 1986, Brain Research.

[30]  M. Raiteri,et al.  Chronic drug treatments induce changes in the sensitivity of presynaptic autoreceptors but not of presynaptic heteroreceptors. , 1983, European journal of pharmacology.

[31]  M. Raiteri,et al.  A simple apparatus for studying the release of neurotransmitters from synaptosomes. , 1974, European journal of pharmacology.

[32]  R. Lem.  [Sleep disturbances and depression: a challenge for antidepressants]. , 2008, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

[33]  P. Bech,et al.  Therapeutic potentials of recently introduced antidepressants. Danish University Antidepressant Group. , 1993, Psychopharmacology series.

[34]  P. Bech,et al.  Therapeutic Potentials of Recently Introduced Antidepressants , 1993 .

[35]  Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group. , 1990, Journal of affective disorders.

[36]  N Sitaram,et al.  Sleep and depression. , 1987, Psychopathology.